Medicinal Chemistry News and Research

RSS

Exclusive licensing agreement accelerates PHD inhibitor development for anemia in CKD patients

Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and TaiGen Biotechnology, a listed discovery-based and market-focused pharmaceutical company, as well as TaiGen Biopharmaceuticals, its wholly-owned Beijing subsidiary (both referred to as "TaiGen"), today announced an exclusive pipeline out-licensing collaboration.

12 Dec 2025

AI-guided discovery of selective DGKα inhibitors to overcome checkpoint resistance in solid cancers

Insilico Medicine has developed a new class of small molecule inhibitors targeting diacylglycerol kinase alpha (DGKα) designed to restore T cell function and overcome resistance to immune checkpoint blockades in solid cancers.

12 Dec 2025

Older chemical libraries yield new leads for next-generation COVID-19 antivirals

SARS‑CoV‑2, the virus that causes COVID-19, continues to mutate, with some newer strains becoming less responsive to current antiviral treatments like Paxlovid.

8 Dec 2025

Study shines light on how P2X4 receptor can be inhibited

A study carried out by the University of Bonn and the University Hospital Bonn throws light on how an important receptor can be inhibited.

5 Dec 2025

Generative AI aids discovery of ISM3830's novel scaffold

Casitas B-lineage lymphoma-b (CBLB) is an E3 ubiquitin–protein ligase that functions as an intracellular checkpoint and master negative regulator of T‑cell and natural killer (NK) cell activation, playing a central role in modulating T-cell activation and immune tolerance, and its inhibition enhances T cells and NK cells function, also provides a strategy for the function restoration of exhausted T cells.

1 Dec 2025

New fluorescent labeling method offers high precision and exceptional stability in living cells

A team of researchers at IOCB Prague headed by Dr. Tomáš Slanina has developed a new method for labeling molecules with fluorescent dyes that surpasses existing approaches in both precision and stability.

21 Nov 2025

Molecular bumpers and glues rewire GPCR signaling for next-generation medicines

New research led by the University of Minnesota Medical School demonstrates that molecules acting as "molecular bumpers" and "molecular glues" can rewire G protein-coupled receptor (GPCR) signaling, turning the cell's busiest receptors into precision tools - opening the door to a new generation of safer, smarter medicines.

31 Oct 2025

Novel approaches to understanding EETs and cardiovascular disease

Some products of arachidonic acid have already been well studied: the prostanoids formed by cyclooxygenases are central mediators of inflammation, fever, and pain.

31 Oct 2025

Breakthrough could offer a new therapeutic option for stopping diabetes-induced complications

Researchers from the University at Albany and NYU Grossman School of Medicine have found a way to block a key cellular pathway known to drive chronic inflammation and impaired wound healing in people with diabetes.

30 Oct 2025

Experimental compound reduces cell death, inflammation, and organ damage in diabetes

An experimental compound reduced the cell death, inflammation, and organ damage seen with diabetes.

29 Oct 2025

Discovery offers a breakthrough approach to combat prostate tumor growth

Prostate cancer relies on genetic "switches", called enhancers, that can turn on tumor-promoting genes.

22 Oct 2025

Breakthrough in RNA-targeted drug discovery offers hope against viral diseases

In a quest to develop new antiviral drugs for COVID-19 and other diseases, a collaboration led by scientists at The Wertheim UF Scripps Institute has identified a potential new drug against the virus that causes COVID-19.

6 Oct 2025

New class of antibiotics shows potent activity against multidrug-resistant bacteria

Scientists at the University of Liverpool, working with international collaborators, have discovered Novltex, a groundbreaking new class of antibiotics with potent activity against some of the world's most dangerous multidrug-resistant (MDR) bacteria.

18 Sep 2025

Researchers receive new funding to advance promising therapy for multiple sclerosis

A Canadian-led international research team, spearheaded by Dr. Fang Liu at the Centre for Addiction and Mental Health (CAMH) has received nearly $800,000 US ($1,137,868 CAD) in new funding to advance a promising therapy for multiple sclerosis (MS).

15 Sep 2025

Texas Tech research team earns $3 million renewal to advance stroke therapy

Stroke research aims to understand the brain's self-protective and repair mechanisms. Gaining detailed insight into these mechanisms is crucial as such knowledge could lead to newly developed medications and interventions which mimic or engage the brain's self-protective/repair mechanisms, leading to innovative stroke therapies.

13 Sep 2025

Novel vitamin K analogs show promise for reversing neurodegenerative diseases

Neurodegenerative diseases like Alzheimer's, Parkinson's, and Huntington's disease are characterized by the progressive loss of neurons.

13 Sep 2025

TRIMTECH Therapeutics establishes Scientific Advisory Board

TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates, to combat neurodegenerative diseases, today announced the formation of its Scientific Advisory Board (SAB).

From TRIMTECH Therapeutics 3 Sep 2025

How plant compounds could target Alzheimer’s disease from multiple angles

This review highlights how dietary polyphenols modulate Alzheimer’s disease biology through antioxidant, anti-inflammatory, and multi-target mechanisms, supported by in-silico docking analyses. Despite promise, challenges in bioavailability and brain delivery remain key hurdles to clinical translation.

31 Aug 2025

New oral antiretroviral shows potential as long-acting HIV pre-exposure prophylaxis

A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, USA, published August 26th in the open-access journal PLOS Biology.

26 Aug 2025

Balancing speed and selectivity is key for designing effective targeted covalent inhibitors

One class of drugs that has shown promise in treating diseases ranging from lung cancer to COVID-19 are targeted covalent inhibitors (TCIs).

22 Aug 2025